First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Solid Tumor, Adult
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Centr Georges Francois Leclerc, Dijon, France
Institut Regional Du Cancer De Montpellier, Montpellier, France
Institut Curie, Paris, France
Contact: Study coordinator (Christophe LE TOURNEAU, MD) · christophe.letourneau@curie.fr · +33144324086Institut Gustave Roussy, Paris, France
Contact: Study coordinator (Aurélien MARABELLE, MD) · aurelien.marabelle@gustaveroussy.fr · +33142115592Hospital Universitari Vall D Hebron, Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
Contact: Study coordinator (Victor MORENO GARCIA, MD) · victor.moreno@startmadrid.com · +34915504800Clinica Universidad De Navarra, Pamplona, Spain
Hospital Clinico Universitario De Valencia, Valencia, Spain
Study leads
Pejvack Motlagh, MD
Study Director
Egle Therapeutics